Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors

Seo Yeon Yoon; Young Bae Kwon; Hyun Woo Kim; Dae Hyun Roh; Seuk Yun Kang; Chan Young Kim; Ho Jae Han; Kee Won Kim; Il Suk Yang; Alvin J. Beitz; Jang Hern Lee

doi:10.1016/j.neuropharm.2004.12.024

Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors

Seo Yeon Yoon, Young Bae Kwon, Hyun Woo Kim, Dae Hyun Roh, Seuk Yun Kang, Chan Young Kim, Ho Jae Han, Kee Won Kim, Il Suk Yang, Alvin J. Beitz, Jang Hern Lee

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Intrathecal (IT) injection of neostigmine (a cholinesterase inhibitor) has been reported to produce a significant anti-nociceptive effect in a number of inflammatory pain models. However, a potential anti-inflammatory effect of IT neostigmine in these models has not been investigated. In the present study, we have examined the 'anti-inflammatory effect of IT injection of neostigmine' (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release. IT neostigmine was found to suppress both leukocyte migration and MPO degranulation in a dose dependent manner. We then established which subtypes of cholinergic receptors were involved in this AI-NEO. IT pretreatment with atropine (a muscarinic receptor antagonist) but not hexamethonium (a nicotinic receptor antagonist) completely blocked the IT neostigmine anti-inflammatory effect. Subsequent experiments showed that IT pretreatment with methoctramine (a muscarinic type 2 (M₂) receptor antagonist), but not pirenzepine (M₁ receptor antagonist) or 4-DAMP (M₃ receptor antagonist), suppressed the AI-NEO. We then evaluated whether adrenal glandular activity was important in the AI-NEO. Adrenalectomy significantly blocked the AI-NEO, while intraperitoneal pretreatment with the β-adrenoceptor antagonist (propranolol), but not the corticosteroid antagonist (RU486) reversed AI-NEO. In conclusion, these results indicate that IT neostigmine facilitates the activation of spinal M₂ receptors and this activation ultimately leads to release of adrenal catecholamines which contribute to the anti-inflammatory effect observed at the site of tissue inflammation.

Original language	English (US)
Pages (from-to)	275-282
Number of pages	8
Journal	Neuropharmacology
Volume	49
Issue number	3
DOIs	https://doi.org/10.1016/j.neuropharm.2004.12.024
State	Published - Sep 2005

Bibliographical note

Funding Information:
This research was supported by a grant (M103KV010009 03K2201 00940) from Brain Research Center of the 21st Century Frontier Research Program funded by the Ministry of Science and Technology of Republic of Korea. The publication of this manuscript was also supported by a grant (R01-2005-000-10580-0) from the Basic Research Program of the Korea Science & Engineering Foundation as well as the Brain Korea 21 project.

Keywords

Acetylcholine
Adrenal medulla
Inflammation
Muscarinic type 2 receptor
Neostigmine
Spinal cord

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.neuropharm.2004.12.024

Find It

Find It at U of M Libraries

Cite this

Yoon, S. Y., Kwon, Y. B., Kim, H. W., Roh, D. H., Kang, S. Y., Kim, C. Y., Han, H. J., Kim, K. W., Yang, I. S., Beitz, A. J., & Lee, J. H. (2005). Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors. Neuropharmacology, 49(3), 275-282. https://doi.org/10.1016/j.neuropharm.2004.12.024

Yoon, SY, Kwon, YB, Kim, HW, Roh, DH, Kang, SY, Kim, CY, Han, HJ, Kim, KW, Yang, IS, Beitz, AJ & Lee, JH 2005, 'Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors', Neuropharmacology, vol. 49, no. 3, pp. 275-282. https://doi.org/10.1016/j.neuropharm.2004.12.024

@article{702b54a4bbdd49d0a561076800bbf628,

title = "Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors",

abstract = "Intrathecal (IT) injection of neostigmine (a cholinesterase inhibitor) has been reported to produce a significant anti-nociceptive effect in a number of inflammatory pain models. However, a potential anti-inflammatory effect of IT neostigmine in these models has not been investigated. In the present study, we have examined the 'anti-inflammatory effect of IT injection of neostigmine' (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release. IT neostigmine was found to suppress both leukocyte migration and MPO degranulation in a dose dependent manner. We then established which subtypes of cholinergic receptors were involved in this AI-NEO. IT pretreatment with atropine (a muscarinic receptor antagonist) but not hexamethonium (a nicotinic receptor antagonist) completely blocked the IT neostigmine anti-inflammatory effect. Subsequent experiments showed that IT pretreatment with methoctramine (a muscarinic type 2 (M2) receptor antagonist), but not pirenzepine (M1 receptor antagonist) or 4-DAMP (M3 receptor antagonist), suppressed the AI-NEO. We then evaluated whether adrenal glandular activity was important in the AI-NEO. Adrenalectomy significantly blocked the AI-NEO, while intraperitoneal pretreatment with the β-adrenoceptor antagonist (propranolol), but not the corticosteroid antagonist (RU486) reversed AI-NEO. In conclusion, these results indicate that IT neostigmine facilitates the activation of spinal M2 receptors and this activation ultimately leads to release of adrenal catecholamines which contribute to the anti-inflammatory effect observed at the site of tissue inflammation.",

keywords = "Acetylcholine, Adrenal medulla, Inflammation, Muscarinic type 2 receptor, Neostigmine, Spinal cord",

author = "Yoon, {Seo Yeon} and Kwon, {Young Bae} and Kim, {Hyun Woo} and Roh, {Dae Hyun} and Kang, {Seuk Yun} and Kim, {Chan Young} and Han, {Ho Jae} and Kim, {Kee Won} and Yang, {Il Suk} and Beitz, {Alvin J.} and Lee, {Jang Hern}",

note = "Funding Information: This research was supported by a grant (M103KV010009 03K2201 00940) from Brain Research Center of the 21st Century Frontier Research Program funded by the Ministry of Science and Technology of Republic of Korea. The publication of this manuscript was also supported by a grant (R01-2005-000-10580-0) from the Basic Research Program of the Korea Science & Engineering Foundation as well as the Brain Korea 21 project.",

year = "2005",

month = sep,

doi = "10.1016/j.neuropharm.2004.12.024",

language = "English (US)",

volume = "49",

pages = "275--282",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity

T2 - Involvement of spinal muscarinic type 2 receptors

AU - Yoon, Seo Yeon

AU - Kwon, Young Bae

AU - Kim, Hyun Woo

AU - Roh, Dae Hyun

AU - Kang, Seuk Yun

AU - Kim, Chan Young

AU - Han, Ho Jae

AU - Kim, Kee Won

AU - Yang, Il Suk

AU - Beitz, Alvin J.

AU - Lee, Jang Hern

N1 - Funding Information: This research was supported by a grant (M103KV010009 03K2201 00940) from Brain Research Center of the 21st Century Frontier Research Program funded by the Ministry of Science and Technology of Republic of Korea. The publication of this manuscript was also supported by a grant (R01-2005-000-10580-0) from the Basic Research Program of the Korea Science & Engineering Foundation as well as the Brain Korea 21 project.

PY - 2005/9

Y1 - 2005/9

N2 - Intrathecal (IT) injection of neostigmine (a cholinesterase inhibitor) has been reported to produce a significant anti-nociceptive effect in a number of inflammatory pain models. However, a potential anti-inflammatory effect of IT neostigmine in these models has not been investigated. In the present study, we have examined the 'anti-inflammatory effect of IT injection of neostigmine' (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release. IT neostigmine was found to suppress both leukocyte migration and MPO degranulation in a dose dependent manner. We then established which subtypes of cholinergic receptors were involved in this AI-NEO. IT pretreatment with atropine (a muscarinic receptor antagonist) but not hexamethonium (a nicotinic receptor antagonist) completely blocked the IT neostigmine anti-inflammatory effect. Subsequent experiments showed that IT pretreatment with methoctramine (a muscarinic type 2 (M2) receptor antagonist), but not pirenzepine (M1 receptor antagonist) or 4-DAMP (M3 receptor antagonist), suppressed the AI-NEO. We then evaluated whether adrenal glandular activity was important in the AI-NEO. Adrenalectomy significantly blocked the AI-NEO, while intraperitoneal pretreatment with the β-adrenoceptor antagonist (propranolol), but not the corticosteroid antagonist (RU486) reversed AI-NEO. In conclusion, these results indicate that IT neostigmine facilitates the activation of spinal M2 receptors and this activation ultimately leads to release of adrenal catecholamines which contribute to the anti-inflammatory effect observed at the site of tissue inflammation.

AB - Intrathecal (IT) injection of neostigmine (a cholinesterase inhibitor) has been reported to produce a significant anti-nociceptive effect in a number of inflammatory pain models. However, a potential anti-inflammatory effect of IT neostigmine in these models has not been investigated. In the present study, we have examined the 'anti-inflammatory effect of IT injection of neostigmine' (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release. IT neostigmine was found to suppress both leukocyte migration and MPO degranulation in a dose dependent manner. We then established which subtypes of cholinergic receptors were involved in this AI-NEO. IT pretreatment with atropine (a muscarinic receptor antagonist) but not hexamethonium (a nicotinic receptor antagonist) completely blocked the IT neostigmine anti-inflammatory effect. Subsequent experiments showed that IT pretreatment with methoctramine (a muscarinic type 2 (M2) receptor antagonist), but not pirenzepine (M1 receptor antagonist) or 4-DAMP (M3 receptor antagonist), suppressed the AI-NEO. We then evaluated whether adrenal glandular activity was important in the AI-NEO. Adrenalectomy significantly blocked the AI-NEO, while intraperitoneal pretreatment with the β-adrenoceptor antagonist (propranolol), but not the corticosteroid antagonist (RU486) reversed AI-NEO. In conclusion, these results indicate that IT neostigmine facilitates the activation of spinal M2 receptors and this activation ultimately leads to release of adrenal catecholamines which contribute to the anti-inflammatory effect observed at the site of tissue inflammation.

KW - Acetylcholine

KW - Adrenal medulla

KW - Inflammation

KW - Muscarinic type 2 receptor

KW - Neostigmine

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=23444431804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444431804&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2004.12.024

DO - 10.1016/j.neuropharm.2004.12.024

M3 - Article

C2 - 15922370

AN - SCOPUS:23444431804

SN - 0028-3908

VL - 49

SP - 275

EP - 282

JO - Neuropharmacology

JF - Neuropharmacology

IS - 3

ER -

Intrathecal neostigmine reduces the zymosan-induced inflammatory response in a mouse air pouch model via adrenomedullary activity: Involvement of spinal muscarinic type 2 receptors

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this